MOBILITY

Here is the complete, source-grounded breakdown for every medication covered in your mobility materials:

1. Benztropine (Class: Anticholinergic)

  • Therapeutic Indication: Specifically indicated to treat involuntary parkinsonian symptoms (rigidity, tremor, bradykinesia, postural instability) and drug-induced parkinsonism.

  • Route of Administration: Oral (PO), Intramuscular (IM), and Intravenous (IV).

  • Contraindications / Precautions: Hypersensitivity and dementia in children.

  • Cautions: Caution in patients with tachycardia, cardiac disease, autonomic neuropathy, prostatic hypertrophy, existing psychosis, glaucoma, myasthenia gravis, hyperthermia, alcohol use disorder, urinary retention or obstruction, exposure to high ambient temperatures, older adults, pregnancy, and breastfeeding.

  • Side Effects & Adverse Effects:

    • Expected Anticholinergic Effects: Constipation, drowsiness, dizziness, blurred vision, dry mouth, weakness, mydriasis, paresthesias, anhidrosis, and hyperthermia.

    • Neurological & Psychiatric Side Effects: Confusion, depression, psychosis, and hallucinations.

    • Urinary Side Effects: Urinary retention.

    • Adverse Reactions: Tachycardia, ocular hypertension, and heat stroke.

    • Life-Threatening Adverse Reactions: Paralytic ileus and coma.

  • Nursing Considerations & Patient Education:

    • Assessments: Regularly assess parkinsonian and extrapyramidal symptoms, bowel function, and intake/output for urinary retention.

    • Behavioral Alerts: Assess for pre-existing mental illness; if behavior changes are observed, hold the medication and report immediately to the healthcare provider.

    • Oral Administration: Give PO doses with food or immediately after meals to avoid GI upset; tablets may be crushed if the patient has difficulty swallowing.

    • Parenteral Monitoring: For IM or IV administration, monitor vital signs closely and keep the patient on bed rest for approximately 1 hour post-injection.

    • Drug Interactions: Anticholinergic side effects increase when co-administered with phenothiazines, tricyclic antidepressants (TCAs), or other anticholinergics.

2. Carbidopa-Levodopa (Class: Dopaminergic)

  • Therapeutic Indication: Primary pharmacotherapy for Parkinson's disease and parkinsonism to relieve tremor and rigidity. Levodopa crosses into brain cells to convert into dopamine; carbidopa inhibits peripheral breakdown of levodopa so more active drug reaches the CNS.

  • Route of Administration: Oral (PO); available in immediate-release (IR) and extended-release (ER) formulations.

  • Contraindications / Precautions: Hypersensitivity, closed-angle glaucoma, cardiovascular disease, hepatic disease, pulmonary disease, concurrent MAOI therapy, dyskinesia, and suspicious skin lesions (can activate malignant melanoma).

  • Cautions: Peptic ulcer disease, existing impulse control disorders, orthostatic hypotension, history of myocardial infarction, psychosis, seizure disorders, glaucoma, and Henoch-Schönlein purpura.

  • Side Effects & Adverse Effects:

    • Side Effects: Anorexia, nausea, vomiting, dysphagia, tardive dyskinesia, erythema, fatigue, dizziness, headache, dry mouth, constipation, bitter taste, twitching, blurred vision, insomnia, psychotic behavior, excessive dark sweating, and urine discoloration (red, brown, or black).

    • Adverse Reactions: Involuntary movements, angioedema, orthostatic hypotension, urinary retention, priapism, psychosis, depression with suicidal ideation, hallucinations, sudden sleep onset, and impulse control behaviors.

    • Abrupt Discontinuation Risk: Abrupt withdrawal may trigger Neuroleptic Malignant Syndrome (NMS).

  • Nursing Considerations & Patient Education:

    • CRITICAL TIMING RULE: Must be administered on time every single time. If a dose is missed, Parkinson's symptoms immediately re-emerge; standard hospital administration windows should not be applied to this medication.

    • Monitoring: Assess parkinsonian symptoms and monitor for the "on-and-off phenomenon" (sudden onset or resolution of mobility symptoms). Monitor vital signs and watch for GI complications (abdominal pain, prolonged constipation, melanotic stools).

    • Toxicity / Overdose Signs: Watch for involuntary muscle twitching, facial grimacing, spasmodic eyewinking, exaggerated tongue protrusion, and acute behavioral changes.

    • Laboratory Changes: Can cause a false-positive Coombs test, elevated serum glucose, false-positive urine dipstick for ketones, decreased hemoglobin/hematocrit, and elevated WBCs; monitor hepatic and renal lab values.

    • Drug Interactions: MAOIs (hypertensive crisis risk), anticholinergics/antipsychotics (reduced levodopa efficacy), TCAs (dyskinesia/hypertension), and methyldopa (psychosis).

3. Ropinirole (Class: Dopamine Agonist)

  • Therapeutic Indication: Indicated for Parkinson's disease and Restless Legs Syndrome (RLS) by directly stimulating dopamine receptors in the brain.

  • Route of Administration: Oral (PO); available in immediate-release (IR) and extended-release (ER) formulations.

  • Contraindications / Precautions: Hypersensitivity, major psychotic disorders, and existing impulse control / compulsive behaviors.

  • Cautions: Hepatic impairment, cardiac disease, pregnancy, lactation, pediatric patients, and older adults (who carry a significantly higher risk of developing hallucinations).

  • Side Effects & Adverse Effects:

    • Side Effects: Neurological, cardiac, and gastrointestinal side effects.

    • Adverse Reactions: Hypotension or hypertension, syncope, and heart rate fluctuations.

    • Severe Alerts: Sudden sleep attacks, sudden/intense compulsive urges (e.g., gambling, hypersexuality, binge eating), and psychotic behavior.

  • Nursing Considerations & Patient Education:

    • Safety Education: Monitor vital signs and observe for psychotic behavior. Educate patients explicitly regarding the drug's strong sedating effects and warn them about driving or operating machinery.

    • Administration: May be taken with or without food.

    • CRITICAL TAPER REQUIREMENT: Must be tapered gradually when stopping therapy; abrupt discontinuation causes severe withdrawal symptoms such as apathy, fatigue, insomnia, sweating, and pain.

    • Drug Interactions: CYP1A2 inhibitors (e.g., ciprofloxacin) increase drug levels; CYP1A2 inducers (e.g., cigarette smoking) decrease drug levels; estrogens increase effects. May potentiate levodopa effects, which may allow for a reduced levodopa dosage.

4. Cyclobenzaprine (Class: Centrally Acting Muscle Relaxant)

  • Therapeutic Indication: Short-term treatment of muscle spasms and acute pain associated with traumatic injuries or muscle spasticity; acts centrally (likely at the brainstem level) without directly affecting the neuromuscular junction.

  • Route of Administration: Oral (PO).

  • Contraindications / Precautions: Acute myocardial infarction, cardiac arrhythmias, AV block, bundle branch block, heart failure, QT prolongation, hyperthyroidism, and concurrent MAOI therapy.

  • Cautions: Seizure disorders, chronic alcohol use, prostatic hypertrophy, urinary retention, hepatic disease, breastfeeding, driving/operating heavy machinery, high sunlight/UV exposure, and older adults (increased morbidity). Note: Unlike most other muscle relaxants, cyclobenzaprine does not carry a risk of drug dependence.

  • Side Effects & Adverse Effects:

    • Side Effects: Anticholinergic effects (blurred vision, dry mouth, constipation, urinary retention, confusion, drowsiness), nausea, nervousness, sinus tachycardia, and palpitations.

    • Adverse Reactions: Allergic reactions, angioedema, myocardial infarction, seizures, paralytic ileus, and stroke.

  • Nursing Considerations & Patient Education:

    • Serotonin Syndrome: Assess patients (especially older adults) for Serotonin Syndrome—monitor for mental status changes (agitation, hallucinations, coma), autonomic instability (tachycardia, labile BP, hyperthermia), and neuromuscular aberrations.

    • Administration & Safety: Administer with meals to avoid GI upset. Observe for drowsiness and instruct patients to avoid concurrent alcohol or CNS depressants.

    • Metabolism & Elimination: Metabolized by the liver and excreted by the kidneys; monitor carefully in hepatic or renal impairment.

    • Drug Interactions: Increased CNS depression when combined with alcohol, kava, valerian, barbiturates, narcotics, promethazine, TCAs, or other CNS depressants.

5. Baclofen (Class: Centrally Acting Muscle Relaxant)

  • Therapeutic Indication: Management of reversible muscle spasticity associated with chronic neuromuscular conditions such as Multiple Sclerosis (MS) by inhibiting reflexes at the spinal cord level.

  • Route of Administration: Oral (PO) and Intrathecal (IT).

  • Contraindications / Precautions: Hypersensitivity.

  • Cautions: Patients who rely on spasticity to maintain posture and balance, epilepsy/seizure disorders (lowers seizure threshold), renal impairment, pregnancy, lactation, children under 4 years of age (for intrathecal route), and older adults (increased risk of CNS side effects).

  • Side Effects & Adverse Effects:

    • Side Effects: Confusion, coma, GI disturbances (constipation), depression, dyspnea, hypotension, and impotence.

    • Adverse Reactions (Acute Overdose / Abrupt Withdrawal): Somnolence, hypotonia, severe respiratory depression, seizures, coma, and cardiovascular instability.

  • Nursing Considerations & Patient Education:

    • BLACK BOX WARNING: Do not discontinue abruptly. Tapering is strictly required to prevent life-threatening withdrawal symptoms.

    • Assessment: Assess muscle spasticity baseline and response, observe for drowsiness/dizziness, and monitor serum glucose and liver function tests (can alter labs).

    • Oral Administration: Administer PO doses with food or milk to minimize GI discomfort.

    • Intrathecal Administration: Resuscitation equipment must be immediately available at the bedside during intrathecal administration in the event of respiratory or cardiac arrest.

    • Drug Interactions: Combined use with other CNS depressants or MAOIs accentuates CNS depression and increases hypotensive risks.

💡 Would you like me to create a practice quiz or study guide based on these drug details to help test your retention?